SheebaKoshy(Koshy)ThomasMD

PubMed

• Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant.
  Curtis Marcoux, Sarah Pasyar, Denái R Milton, Hina N Khan, Mark R Tanner
  British Journal of Haematology. 2024-11-28
• Optimal infused CD34cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation.
  Oren Pasvolsky, Curtis Marcoux, Denái R Milton, Babar Pal, Mark R Tanner
  Blood Cancer Journal. 2024-10-31
• Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p.
  Curtis Marcoux, Oren Pasvolsky, Denái R Milton, Mark R Tanner, Qaiser Bashir
  Transplantation and Cellular Therapy. 2024-10-22

Journal Articles

• Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction Drugs  
  Krina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature
• Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191  
  Sheeba K Thomas, Robert Z Orlowski, Hans C Lee, Clinical Cancer Research
• Phase I Study of an Active Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma with DNA Vaccines Encoding Antigen-Chemokine Fusion: Study Protocol  
  Sattva S Neelapu, D Lynne Smith, Vincent Y Lee, Larry W Kwak, Sheeba K Thomas, BioMed Central

Abstracts/Posters

• Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Re...
  Sheeba K. Thomas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-HodgkinÍs Lymphoma and C...
  Sheeba K. Thomas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
  Sheeba K. Thomas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
  Sheeba K. Thomas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Phase I trial of a novel DNA vaccine in patients (pts) with smoldering Waldenstrom macroglobulinemia (sWM). 
  2019 ASCO Annual Meeting - 6/1/2019
• Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Outcome of Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myel... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all